Question to the Cabinet Office:

To ask His Majesty's Government what estimate they have made of the cost of the proposals included in the UK–EU reset agreement, published on 19 May, in particular the proposed sanitary and phytosanitary agreement; and what assessment they have made of the impact of that agreement on the UK's international trade deals with other trading blocs, including pharmaceutical tariffs.

Following the first UK-EU Summit in 2025, the Government published its assessment of the SPS agreement and the agreement to link Emissions Trading Systems. These measures alone are set to add nearly £9 billion a year to the UK economy by 2040.

This government has also agreed significant trade deals with the US and India. For example, the UK is the only country with wide reaching zero tariff commitments on pharmaceuticals with the US. In 2024, UK exports of pharmaceutical products to the US were worth over £5 billion. The manufacture of pharmaceutical products contributed £25 billion to the UK economy in 2024. The SPS deal with the EU does not affect this.